Boule Diagnostics Overview
- Year Founded
-
1992
- Status
-
Public
- Employees
-
178
- Stock Symbol
-
BOUL
- Investments
-
2
- Share Price
-
$0.13
- (As of Monday Closing)
Boule Diagnostics General Information
Description
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
Contact Information
Website
www.boule.comCorporate Office
- Fagerstagatan 7
- 163 53 Spanga
- Sweden
Corporate Office
- Fagerstagatan 7
- 163 53 Spanga
- Sweden
Boule Diagnostics Stock Performance
As of 16-Nov-2026, Boule Diagnostics’s stock price is $0.13. Its current market cap is $4.91M with 38.8M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.13 | $0.12 | $0.09 - $0.66 | $4.91M | 38.8M | 313K | -$0.05 |
Boule Diagnostics Financials Summary
As of 30-Sep-2026, Boule Diagnostics has a trailing 12-month revenue of $45.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 29,791 | 40,875 | 46,321 | 57,085 |
| Revenue | 45,783 | 49,843 | 52,805 | 53,751 |
| EBITDA | 458 | 4,358 | (30,746) | 6,368 |
| Net Income | (1,841) | (382) | (28,043) | 2,350 |
| Total Assets | 46,368 | 51,028 | 46,849 | 75,556 |
| Total Debt | 21,658 | 24,316 | 17,679 | 16,627 |
Boule Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Boule Diagnostics Patents
Boule Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2020501114-A | Method and device for counting platelets in capillary blood | Active | 11-Nov-2016 | ||
| ES-2874180-T3 | Method and device for counting thrombocytes in capillary blood | Active | 11-Nov-2016 | ||
| EP-3538887-A1 | Method and device for thrombocyte counting in capillary blood | Active | 11-Nov-2016 | ||
| EP-3538887-B1 | Method and device for thrombocyte counting in capillary blood | Active | 11-Nov-2016 | ||
| US-20200096530-A1 | Method and device for thrombocyte counting in capillary blood | Inactive | 11-Nov-2016 | G01N35/1095 |
Boule Diagnostics Signals
Boule Diagnostics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Boule Diagnostics Investments & Acquisitions (2)
Boule Diagnostics’s most recent deal was a Later Stage VC with Biosurfit for . The deal was made on 14-Dec-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biosurfit | 14-Dec-2018 | Later Stage VC | Diagnostic Equipment | ||
| Drew Scientific (2280 hematology platform and laser module product line) | 18-Apr-2018 | Merger/Acquisition | Laboratory Services (Healthcare) |
Boule Diagnostics ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
30.03 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Healthcare
Industry
of 665
Rank
Percentile
Medical Devices
Subindustry
of 235
Rank
Percentile
Boule Diagnostics Exits (1)
Boule Diagnostics’s most recent exit was on 14-Dec-2018 from Biosurfit. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Biosurfit | 14-Dec-2018 | Completed |
|
Boule Diagnostics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Boule Medical | Spaanga, Sweden | 1969 |
Boule Diagnostics FAQs
-
When was Boule Diagnostics founded?
Boule Diagnostics was founded in 1992.
-
Where is Boule Diagnostics headquartered?
Boule Diagnostics is headquartered in Spanga, Sweden.
-
What is the size of Boule Diagnostics?
Boule Diagnostics has 178 total employees.
-
What industry is Boule Diagnostics in?
Boule Diagnostics’s primary industry is Diagnostic Equipment.
-
Is Boule Diagnostics a private or public company?
Boule Diagnostics is a Public company.
-
What is Boule Diagnostics’s stock symbol?
The ticker symbol for Boule Diagnostics is BOUL.
-
What is the current stock price of Boule Diagnostics?
As of 16-Nov-2026 the stock price of Boule Diagnostics is $0.13.
-
What is the current market cap of Boule Diagnostics?
The current market capitalization of Boule Diagnostics is $4.91M.
-
What is Boule Diagnostics’s current revenue?
The trailing twelve month revenue for Boule Diagnostics is $45.8M.
-
What is Boule Diagnostics’s annual earnings per share (EPS)?
Boule Diagnostics’s EPS for 12 months was -$0.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process